Dr. Harry Bear on Translating Pathological Complete Response to OS Benefits

Video

Bear discusses studies adding treatments to chemotherapy in order to increase the pathological complete response (pCR) rate and the difficulties of translating those benefits into better overall survival (OS) rates for patients with breast cancer.

Harry Bear, MD, PhD, chair, Surgical Oncology, Virginia Commonwealth University Health, discusses studies adding treatments to chemotherapy in order to increase the pathological complete response (pCR) rate and the difficulties of translating those benefits into better overall survival (OS) rates for patients with breast cancer. Bear says in order to impact OS, the treatment a patient is given must greatly impact their pCR.

Related Videos
Video 7 - "Unmet Needs and Future Directions in HER2+ Breast Cancer"
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Video 4 - "KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer"
Video 3 - "APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer"
Related Content
Lumisight, Lumicell DVS Gains FDA Approval to Detect Residual Breast Cancer

Lumisight, Lumicell DVS Gains FDA Approval to Detect Residual Breast Cancer

April 18th 2024
Article

The FDA has approved Lumisight and the Lumicell Direct Visualization System for fluorescence imaging in adult patients with breast cancer.

Read More

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022
Podcast

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Listen

Improving Identification Within Asian American Subgroups With Ovarian Cancer

Improving Identification Within Asian American Subgroups With Ovarian Cancer

April 12th 2024
Article

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.

Read More

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

September 25th 2020
Podcast

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Listen

The Allina Health Approach to Genomic Testing for Cancer

The Allina Health Approach to Genomic Testing for Cancer

April 11th 2024
Article

In an interview with Targeted Oncology, Sara Kerr, MD discussed the evolution of genomic testing for patients with cancer and highlighted the program used at Allina Health.

Read More

Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL

Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL

April 10th 2024
Article

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.

Read More